

**Virginia Medicaid**  
**Pharmacy & Therapeutics Committee Meeting**  
Agenda  
*600 East Broad Street – 1st Floor Conference Rooms*  
*Richmond, VA 23219*  
**Thursday, April 16, 2026 – 1 PM – 4 PM**

<b>Welcome and Comments</b>	<b>Steve Ford, Medicaid Director</b>
<b>Call to Order</b>	<b>Greg Barabell, MD, Chief Medical Officer, Chair</b>
<b>Drug Utilization Review (DUR) Board Report</b>	<b>Rachel Cain, PharmD</b>
<b>Approval of Minutes from January 29, 2026 Meeting</b>	<b>P&amp;T Committee Members</b>
<b>Old Business</b> <ul style="list-style-type: none"><li>• <b>Bylaws</b></li></ul>	<b>P&amp;T Committee Members</b>
<b>PDL (PREFERRED DRUG LIST) Management</b>	<b>P&amp;T Committee Members</b>
<b>PDL Off Cycle – New Drug Review (<i>Therapeutic Class</i>)</b>  <b><u>Brand Drugs</u></b>	
<b>PDL Quarter 2 – Annual Review: Classes with updates</b>  <b><u>Analgesics</u></b> <ul style="list-style-type: none"><li>• Antimigraine Agents</li><li>• Antimigraine Agents Other (<b>Closed Class</b>)</li><li>• Non-Steroidal Anti-Inflammatory Drugs (NSAID) (includes Cox-2 inhibitors and topical agents)</li><li>• Opioids: Long Acting</li><li>• Opioid Dependency Treatment Agents (<b>Closed Class</b>) (includes oral buprenorphine)</li><li>• Opioids: Short Acting (includes combination drugs and lozenges)</li></ul> <b><u>Antibiotics / Anti-Infectives</u></b> <ul style="list-style-type: none"><li>• Antifungal (oral)</li><li>• Antibiotics (topical)</li><li>• Cephalosporins (Second and Third Generations)</li><li>• Gastrointestinal</li><li>• Ketolides &amp; Macrolides (Adult and Pediatric)</li><li>• Quinolones (Second and Third Generations)</li><li>• Quinolones (Otic)</li></ul> <b><u>Antivirals</u></b> <ul style="list-style-type: none"><li>• Antivirals for Herpes (HSV)</li><li>• Antivirals for Influenza</li></ul> <b><u>Cardiac</u></b> <ul style="list-style-type: none"><li>• Anticoagulants (<i>including oral agents, low molecular weight heparins &amp; Factor XA Inhibitors</i>) (<b>Closed Class</b>)</li><li>• Platelet Aggregation Inhibitors</li></ul> <b><u>Contraceptives</u></b> <ul style="list-style-type: none"><li>• Long-Acting Reversible Contraceptives (LARCS) (includes long-acting IUDs &amp; injectable)</li></ul>	

**Dermatologic Agents (Topical)**

- Acne Agents (includes benzoyl peroxide, clindamycin, retinoids & combinations)
- Antifungal Agents, Topical
- Psoriasis Agents
- Rosacea Agents

**Respiratory**

- Immunomodulators, Asthma (Closed class)

**PDL Quarter 2 – Annual Review: Therapeutic Classes without Significant Updates (reviewed by the Department)**  
**TBD**

**Confidential Meeting (Pricing Information Discussion) P&T Committee Members & DMAS Staff**

**Criteria Discussion of Off Cycle New Drugs P&T Committee Members**

**Criteria Discussion of Quarter 2 Drugs P&T Committee Members**

*\*Criteria discussions will be held for classes only if deemed PDL eligible by the P&T Committee during Drug Class Discussions.*

**Weight Management Agents SA Form Review (Wegovy Tablet) P&T Committee Members**

**Other Business Chair**

**Next Meeting – July 16th, 2026 (tentative) Chair**

**Oral Presentations:** The P&T Committee, in conjunction with the Department, will be allocating time slots for interested parties to present scientific and clinical information on **only** the drug classes scheduled for review at the April meeting and new drugs in PDL Off Cycle listed on the Agenda. **All presentations must include information published in a peer-reviewed journal (per guidelines below) that is clinical in nature and based on scientific material. The references used to support presentations must be within the following timeframes:**

- PDL Quarter 2 Annual Reviews – April 2025 to present.
- Off Cycle New Drugs – April 2024 to present.

No anecdotal accounts are to be given. Each speaker will be allocated no more than 2 minutes to present. Speakers will be decided by the Chairperson based on relevancy of the information. **Speakers must receive confirmation to verify the presentation is scheduled.**

**Anyone interested in providing specific clinical information to the Committee at the meeting must submit an outline of discussion points, clinical references (within the stated guidelines above) and a written request to speak with the name/title of the presenter.** Please send requested information to [pdlinput@dmass.virginia.gov](mailto:pdlinput@dmass.virginia.gov) and [david.damico@primetherapeutics.com](mailto:david.damico@primetherapeutics.com) by 5 p.m. EST on Friday, March 13, 2026.

**Written information/comments:** The P&T Committee will also accept written comments for consideration. Please send statements to [pdlinput@dmass.virginia.gov](mailto:pdlinput@dmass.virginia.gov) by 5 p.m. EST Friday, March 13, 2026.